Thursday, 15 October 2026European Markets

ORPEA Stock 10.06% Up On Thursday

Loading stream...

(vianews) - the market ended the session with orpea (orp.pa) jumping 10.06% to €0.99 on thursday, after three sequential sessions in a row of losses. cac 40 jumped 1.85% to €7,060.69, after three sequential sessions in a row of gains, on what was an all-around up trend exchanging session today.

orpea's last close was €0.90, 90.7% below its 52-week high of €9.62.

about orpea

orpea sa operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, and laundry and room cleaning, as well as various daily event, entertainment, and therapeutic workshop services. the company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, psychosomatic conditions, and post-traumatic stress disorder conditions, as well as geriatric, child, young adult, parent-child, and public/private patients psychiatry services. in addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. the company operates in france, belgium, spain, italy, ireland, switzerland, austria, germany, the czech republic, poland, the netherlands, luxembourg, portugal, brazil, russia, slovenia, uruguay, colombia, mexico, chile, latvia, croatia, and china. orpea sa was founded in 1989 and is headquartered in puteaux, france.

earnings per share

as for profitability, orpea has a trailing twelve months eps of €-63.9.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -445.48%.

moving average

orpea's value is way under its 50-day moving average of €1.43 and way under its 200-day moving average of €2.36.

yearly top and bottom value

orpea's stock is valued at €0.99 at 21:41 est, under its 52-week low of €1.02.

revenue growth

year-on-year quarterly revenue growth grew by 10.7%, now sitting on 4.93b for the twelve trailing months.

volatility

orpea's last week, last month's, and last quarter's current intraday variation average was a negative 4.26%, a negative 2.25%, and a positive 3.24%.

orpea's highest amplitude of average volatility was 4.33% (last week), 5.20% (last month), and 3.24% (last quarter).

more news about orpea (orp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com